Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04488003
Recruitment Status : Recruiting
First Posted : July 27, 2020
Last Update Posted : May 11, 2022
Information provided by (Responsible Party):
BioMed Valley Discoveries, Inc